Epidemiological characterization of psoriasis in the Central Military Hospital.
Keywords:
Epidemiologic characterization, psoriasis, psoriasis in ColombiaAbstract
Introduction: Psoriasis is a chronic inflammatory disease, mediated by the T lymphocyte. It is characterized by an epidermic hyperproliferation, and lacks of epidemiologic description in the Colombian population. Therefore, it is imperative to establish and observational-follow up model, able to clarify, the origin, related factors, clinic outcome, and disease prognosis in our media, getting information enough to compare its behavior with other populations.
Objective: To describe epidemiologic and clinical characterization in the psoriatic patients, in the dermatology department, Military Central Hospital.
Materials and metods: A cross sectional prospective study was made from a psoriatic cohort of patients: Eighty six (86) patients were included with a clinic and pathological diagnosis of psoriasis, evaluated between July 2007- July 2008 in the dermatology department. A complete medical record was registered including clinical and epidemiological characteristics, psoriasis area and severity index (PASI,) and Dermatology life quality index (DLQI). SPSS 11.5 for windows, statistical software was used.
Results: Eighty six (86) patients were included, 61, 6% male and 38,4% female. The average age was 54; 63% were married and 14% single. The Hispanic race was the most frequent. The majority of patients had begun their disease after 50 years old. Eighty eight (89%) showed vulgar psoriasis, Seven (7%), guttate psoriasis and nail disease was found in twenty six percent (26,7%) of patients, mainly pits and onycholysis. PASI score average was 7,8 showing a mild disease. One hundred percent (100%) of patients had received topical treatment and fifty four percent had used any systemic treatment. Topical glucorticoids and phototherapy were the most used.
Conclusion: The Clinical and epidemiological characterization of psoriatic patients in the Hospital Militar Central, establish the support to run multidisciplinary health projects directed to the effective study and disease management.
Author Biographies
Cesar González
Dermatólogo. Clínica de Psoriasis Hospital Militar Central. Bogotá, Colombia.
Luis Antonio Castro
Dermatólogo. Docente pregrado y postgrado, Universidad Militar Nueva Granada. Clínica de Psoriasis Hospital Militar
Central. Inmunodermatólogo. Clínica Mayo, Rochester MN, USA.
Guillermo De la Cruz
Residente III año de Dermatología, Universidad Militar Nueva Granada. Clínica de Psoriasis Hospital Militar Central
Claudia Marcela Arenas
Residente I año de Dermatología Universidad Militar Nueva Granada. Clínica de Psoriasis Hospital Militar Central.
Adriana Beltrán
Especialista Medicina Interna- Reumatología. Universidad Militar Nueva Granada. Clínica de Psoriasis Hospital Militar Central.Candidata a Maestría en Epidemiología Clínica- Pontificia Universidad Javeriana
Ana María Santos
Bacterióloga- Epidemióloga. Universidad De la Sabana. Clínica de Psoriasis Hospital Militar Central.
References
2. Fonseca D, Aristizábal L, Cruz C, Herrera L, Prada J, De La Cruz G. et al. Inmunología y Terapia Biológica en Psoriasis. Revista Asociación Colombiana de Dermatología y Cirugía Dermatológica. 2007; 15:208 - 18.
3. Li YY, Zollner TM, Schön MP. Targeting leukocyte recruitment in the treatment of psoriasis. Clin Dermatol. 2008; 26:527 - 38.
4. Schön M, Boehncke W. Psoriasis. N Engl J Med. 2005; 352:1899 - 912.
5. Krueger J. The immunologic basic for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002; 46:1-23.
6. van de Kerkhof PC, Kragballe K, Austad J, Berth-Jones J, Cambazard F, de la Brassinne M, et al. Psoriasis: severity assessment in clinical practice. Eur J Dermatol. 2006;16:167-71.
7. van de Kerkhof PC. Options for the treatment of psoriasis: a multifactorial approach. Clin Dermatol. 2008; 26: 419 - 23.
8. Cañarte C, Cabrera F, Palacios S. Epidemiología de la Psoriasis en el Distrito Metropolitano de Quito. Revista Científica Sociedad Ecuatoriana de Dermatología. 2004; 9: 2 - 7.
9. Paciel J, Vignale R. Estudio epidemiológico de la psoriasis inducida por fármacos. Med cutan Iber Lat Am. 2006; 34: 109 - 16.
10. Suite M. The epidemiology of psoriasis in a dermatology clinic in a general hospital in port-of-spain, Trinidad and Tobago, West Indies. West Indian Med. J. 2006; 55.
11. Namazi MR. Why is psoriasis uncommon in Africans? The influence of dietary factors on the expression of psoriasis. Int J Dermatol. 2004; 43: 391 - 2.
12. Trujillo I, Díaz M, Torres O, Torres F, Falcón L, Pérez M. Psoriasis vulgar. Estudio descriptivo de 200 pacientes. Rev Cubana Med. 2002; 4:12- 5.
13. Capon F, Dallapiccola B, Novelli G. Advances in the Search for Psoriasis Susceptibility Genes. Molecular Genetics and Metabolism. 2000; 71:250 - 5.
14. Tsankov N, Angelova I, Kazandjieva R. Drug-induced psoriasis. Recognition and management, Am J Clin Dermatol. 2000; 159 - 65.
15. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol. 2001; 314 - 20.
16. Higgins E. Alcohol, smoking and psoriasis. Clin Exp Dermatol. 2000; 107 - 10.
17. Gupta M.A, Kykby S, Schork NJ, Ellis CN, Voorhees JJ. A psychocutaneous profile of psoriasis patients who are stress reactors. Gen Hosp Psych. 1989; 166 - 73.
18. Menter A, Gottlieb A, Feldman S, Van Voorhees A, Leonardi C, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008; 58: 826 - 50.
19. Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008; 58: 224 - 31.
20. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007; 57: 1 - 27.
21. Felman S, Krueger G. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; ii64 - ii68.
22. Van de Kerkhof PC. Psoriasis. Dermatology Mosby 2003; 125 – 37.
23. De Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002; 138:1221 - 7.
24. Fluhr JW, Cavallotti C, Berardesca E.. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008; 26: 380 - 6.
25. Radtke M, Augustin M. Economic considerations in psoriasis next term management. Clinics in Dermatology. 2008; 26:424 - 31.
26. Lebwohl M, Siskin SB, Epinette W, Breneman D, Funicella T, Kalb R, et al. A multicenter trial of calcipotriene ointment and clobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 2006; 268 - 9.
27. Lebwohl MG, Breneman DL, Goffe BS, Grossman JR, Ling MR, Milbauer, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998; 39: 590 - 6.
28. Schneider L, Hinrichs R, Scharffetter K. Phototherapy and photochemotherapy. Clin Dermatol. 2008; 26: 464 - 76.
29. Feldman S.R. The psoriasis and psoriatic arthritis pocket guide: treatment algorithms and management options. National Psoriasis Foundation, Portland 2005.
30. Warren RB, Griffiths CE. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol. 2008; 26: 438 - 47.
31. Kimball A, Kupper T. Future perspectives of psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. Clin Dermatol. 2008; 26: 554 - 61.
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
